nach oben

Current Gastroenterology Reports

Erschienen in:

01.11.2018 | Liver (S Cotler and E Kallwitz, Section Editors)

Should Sarcopenia Increase Priority for Transplant or Is It a Contraindication?

verfasst von: Guido Stirnimann, Maryam Ebadi, Puneeta Tandon, Aldo J. Montano-Loza

Erschienen in: Current Gastroenterology Reports | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to discuss the current evidence regarding the impact of sarcopenia on patients with cirrhosis awaiting liver transplantation and to determine if its presence should be considered a criterion for expedited transplantation or a contraindication for transplantation.

Recent Findings

Sarcopenia is a negative predictor of survival in patients on a waiting list and after liver transplant. The gut-liver axis and the liver-muscle axis have been explored to understand the complex pathophysiology of sarcopenia.

Summary

Sarcopenia is a frequent finding in patients with cirrhosis. The diagnosis is ideally based on cross-sectional image analysis (CT or MRI) and treatment consists of optimization of caloric and protein intake. To date, prioritizing tools for liver transplantation have not included nutrition or sarcopenia parameters. Patients with a low Model for End-Stage Liver Disease (MELD) or MELD-Na score and sarcopenia would benefit from prioritization for transplant in order to reduce time on waiting list and therefore mortality.

Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012;18(10):1209–16. https://doi.org/10.1002/lt.23495.CrossRefPubMed

Kaido T, Tamai Y, Hamaguchi Y, Okumura S, Kobayashi A, Shirai H, et al. Effects of pretransplant sarcopenia and sequential changes in sarcopenic parameters after living donor liver transplantation. Nutrition. 2017;33:195–8. https://doi.org/10.1016/j.nut.2016.07.002.CrossRefPubMed

Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CMM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7(2):126–35. https://doi.org/10.1002/jcsm.12039.CrossRefPubMed

Hammad A, Kaido T, Hamaguchi Y, Okumura S, Kobayashi A, Shirai H, et al. Impact of sarcopenic overweight on the outcomes after living donor liver transplantation. Hepatobiliary Surg Nutr. 2017;6(6):367–78. https://doi.org/10.21037/hbsn.2017.02.02.CrossRefPubMedPubMedCentral

Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JXQ, et al. Inclusion of sarcopenia within MELD (MELD-sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol. 2015;6. https://doi.org/10.1038/ctg.2015.31.

Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166–73.CrossRefPubMed

Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.CrossRefPubMed

Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130(6):1652–60. https://doi.org/10.1053/j.gastro.2006.02.010.CrossRefPubMed

Gotthardt D, Weiss KH, Baumgartner M, Zahn A, Stremmel W, Schmidt J, et al. Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterol. 2009;9:72. https://doi.org/10.1186/1471-230X-9-72.CrossRefPubMedPubMedCentral

10.

•• van Vugt JLA, Alferink LJM, Buettner S, Gaspersz MP, Bot D, Darwish Murad S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. J Hepatol. 2017;68:707–14. https://doi.org/10.1016/j.jhep.2017.11.030. In this study, the MELD-sarcopenia score has been successfully validated in a national European cohort. CrossRefPubMed

11.

Durand F, Buyse S, Francoz C, Laouenan C, Bruno O, Belghiti J, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol. 2014;60(6):1151–7. https://doi.org/10.1016/j.jhep.2014.02.026.CrossRefPubMed

12.

Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol. 2012;10(2):117–25. https://doi.org/10.1016/j.cgh.2011.08.016.CrossRefPubMed

13.

Norman K, Pirlich M. Gastrointestinal tract in liver disease: which organ is sick? Curr Opin Clin Nutr Metab Care. 2008;11(5):613–9. https://doi.org/10.1097/MCO.0b013e32830a70bc.CrossRefPubMed

14.

Petersen KF, Krssak M, Navarro V, Chandramouli V, Hundal R, Schumann WC, et al. Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis. Am J Phys. 1999;276(3 Pt 1):E529–35.

15.

• Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016;65(6):1232–44. https://doi.org/10.1016/j.jhep.2016.07.040. This is an excellent review on sarcopenia in patients with liver disease including pathophysiology as well as future treatment targets. CrossRefPubMedPubMedCentral

16.

Sinclair M, Gow PJ, Grossmann M, Angus PW. Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther. 2016;43(7):765–77. https://doi.org/10.1111/apt.13549.CrossRefPubMed

17.

Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45(10):2333–47. https://doi.org/10.1016/j.biocel.2013.05.019.CrossRefPubMed

18.

Drummond MJ, Dreyer HC, Fry CS, Glynn EL, Rasmussen BB. Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling. J Appl Physiol. 2009;106(4):1374–84. https://doi.org/10.1152/japplphysiol.91397.2008.CrossRefPubMedPubMedCentral

19.

Tsien C, Davuluri G, Singh D, Allawy A, Ten Have GA, Thapaliya S, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology. 2015;61(6):2018–29. https://doi.org/10.1002/hep.27717.CrossRefPubMed

20.

Qiu J, Thapaliya S, Runkana A, Yang Y, Tsien C, Mohan ML, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism. Proc Natl Acad Sci U S A. 2013;110(45):18162–7. https://doi.org/10.1073/pnas.1317049110.CrossRefPubMedPubMedCentral

21.

Qiu J, Tsien C, Thapalaya S, Narayanan A, Weihl CC, Ching JK, et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012;303(8):E983–93. https://doi.org/10.1152/ajpendo.00183.2012.CrossRefPubMedPubMedCentral

22.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23. https://doi.org/10.1093/ageing/afq034.CrossRefPubMedPubMedCentral

23.

Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr. 2010;29(2):154–9. https://doi.org/10.1016/j.clnu.2009.12.004.CrossRefPubMed

24.

Giusto M, Lattanzi B, Albanese C, Galtieri A, Farcomeni A, Giannelli V, et al. Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur J Gastroenterol Hepatol. 2015;27(3):328–34. https://doi.org/10.1097/MEG.0000000000000274.CrossRefPubMed

25.

Romeiro FG, Augusti L. Nutritional assessment in cirrhotic patients with hepatic encephalopathy. World J Hepatol. 2015;7(30):2940–54. https://doi.org/10.4254/wjh.v7.i30.2940.CrossRefPubMedPubMedCentral

26.

Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97(6):2333–8. https://doi.org/10.1152/japplphysiol.00744.2004.CrossRefPubMed

27.

Montano-Loza AJ. Muscle wasting: a nutritional criterion to prioritize patients for liver transplantation. Curr Opin Clin Nutr Metab Care. 2014;17(3):219–25. https://doi.org/10.1097/MCO.0000000000000046.CrossRefPubMed

28.

van Vugt JL, Levolger S, Gharbharan A, Koek M, Niessen WJ, Burger JW, et al. A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(2):285–97. https://doi.org/10.1002/jcsm.12158.CrossRefPubMed

29.

Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010;211(2):271–8.CrossRefPubMedPubMedCentral

30.

Golse N, Bucur PO, Ciacio O, Pittau G, Sa Cunha A, Adam R, et al. A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. Liver Transpl. 2017;23(2):143–54. https://doi.org/10.1002/lt.24671.CrossRefPubMed

31.

Izumi T, Watanabe J, Tohyama T, Takada Y. Impact of psoas muscle index on short-term outcome after living donor liver transplantation. Turk J Gastroenterol. 2016;27(4):382–8. https://doi.org/10.5152/tjg.2016.16201.CrossRefPubMed

32.

Montano-Loza AJ, Carey EJ, Ebadi M, Wang CW, Dasarathy S, Kappus MR, et al. Skeletal muscle index indicates mortality risk more accurately than psoas muscle index in patients with cirrhosis. From the FLEXIT consortium. J Hepatol. 2018;68:698–9.CrossRef

33.

Tandon P, Low G, Mourtzakis M, Zenith L, Myers RP, Abraldes JG, et al. A model to identify sarcopenia in patients with cirrhosis. Clin Gastroenterol Hepatol. 2016;14(10):1473-80 e3. https://doi.org/10.1016/j.cgh.2016.04.040.CrossRef

34.

Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition. 2005;21(2):113–7.CrossRefPubMed

35.

Wiesinger GF, Quittan M, Zimmermann K, Nuhr M, Wichlas M, Bodingbauer M, et al. Physical performance and health-related quality of life in men on a liver transplantation waiting list. J Rehabil Med. 2001;33(6):260–5.CrossRefPubMed

36.

Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010;16(12):1373–8.CrossRefPubMed

37.

Alameri HF, Sanai FM, Al Dukhayil M, Azzam NA, Al-Swat KA, Hersi AS, et al. Six minute walk test to assess functional capacity in chronic liver disease patients. World J Gastroenterol. 2007;13(29):3996–4001.CrossRefPubMedPubMedCentral

38.

Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R, et al. Results of the first year of the new liver allocation plan. Liver Transpl. 2004;10(1):7–15. https://doi.org/10.1002/lt.20024.CrossRefPubMed

39.

Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11(3):336–43. https://doi.org/10.1002/lt.20329.CrossRefPubMed

40.

Myers RP, Shaheen AA, Faris P, Aspinall AI, Burak KW. Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list. PLoS One. 2013;8(1):e51926. https://doi.org/10.1371/journal.pone.0051926.CrossRefPubMedPubMedCentral

41.

• Carey EJ, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano-Loza AJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl. 2017;23(5):625–33. https://doi.org/10.1002/lt.24750. This multicenter North American publication addresses the optimal definition of sarcopenia in end-stage liver disease. CrossRefPubMedPubMedCentral

42.

Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl. 2017;23(11):1451–64. https://doi.org/10.1002/lt.24848.CrossRefPubMed

43.

Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Muller MJ, et al. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr. 1997;16(2):43–55.CrossRefPubMed

44.

Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25(2):285–94. https://doi.org/10.1016/j.clnu.2006.01.018.CrossRefPubMed

45.

Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol. 2012;27(3):430–41. https://doi.org/10.1111/j.1440-1746.2011.06951.x.CrossRefPubMed

46.

Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38–43. https://doi.org/10.1016/j.jhep.2004.03.023.CrossRefPubMed

47.

Ney M, Abraldes JG, Ma M, Belland D, Harvey A, Robbins S, et al. Insufficient protein intake is associated with increased mortality in 630 patients with cirrhosis awaiting liver transplantation. Nutr Clin Pract. 2015;30(4):530–6. https://doi.org/10.1177/0884533614567716.CrossRefPubMed

48.

Grüngreiff K, Reinhold D, Wedemeyer H. The role of zinc in liver cirrhosis. Ann Hepatol. 2016;15(1):7–16.

49.

Grüngreiff K. Branched amino acids and zinc in the nutrition of liver cirrhosis. J Clin Exp Hepatol. 2018. https://doi.org/10.1016/j.jceh.2018.04.004.

50.

Konstantakis C, Tselekouni P, Kalafateli M, Triantos C. Vitamin D deficiency in patients with liver cirrhosis. Ann Gastroenterol. 2016;29(3):297–306. https://doi.org/10.20524/aog.2016.0037.CrossRefPubMedPubMedCentral

51.

Putz-Bankuti C, Pilz S, Stojakovic T, Scharnagl H, Pieber TR, Trauner M, et al. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int. 2012;32(5):845–51. https://doi.org/10.1111/j.1478-3231.2011.02735.x.CrossRefPubMed

52.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30. https://doi.org/10.1210/jc.2011-0385.CrossRefPubMed

53.

Duarte-Rojo A, Ruiz-Margain A, Montano-Loza AJ, Macias-Rodriguez RU, Ferrando A, Kim WR. Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list. Liver Transpl. 2018;24(1):122–39. https://doi.org/10.1002/lt.24958.CrossRefPubMed

54.

Tandon P, Ismond KP, Riess K, Duarte-Rojo A, Al-Judaibi B, Dunn MA, et al. Exercise in cirrhosis: translating evidence and experience to practice. J Hepatol. 2018. https://doi.org/10.1016/j.jhep.2018.06.017.

55.

Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol. 2001;96(8):2442–7. https://doi.org/10.1111/j.1572-0241.2001.04051.x.CrossRefPubMed

56.

Rössle M. TIPS: 25 years later. J Hepatol. 2013;59(5):1081–93. https://doi.org/10.1016/j.jhep.2013.06.014.

57.

DiMartini A, Cruz RJ Jr, Dew MA, Myaskovsky L, Goodpaster B, Fox K, et al. Muscle mass predicts outcomes following liver transplantation. Liver Transpl. 2013;19(11):1172–80. https://doi.org/10.1002/lt.23724.CrossRefPubMedPubMedCentral

58.

• Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant. 2013;13(6):1549–56. Short-term survival after living donor liver transplantation is associated with pre-transplant sarcopenia, as has been demonstrated in this publication. CrossRefPubMed

59.

van Vugt JLA, Buettner S, Alferink LJM, Bossche N, de Bruin RWF, Darwish Murad S, et al. Low skeletal muscle mass is associated with increased hospital costs in patients with cirrhosis listed for liver transplantation-a retrospective study. Transpl Int. 2018;31(2):165–74. https://doi.org/10.1111/tri.13048.CrossRefPubMed

60.

Linecker M, Krones T, Berg T, Niemann CU, Steadman RH, Dutkowski P, et al. Potentially inappropriate liver transplantation in the era of the “sickest first” policy - a search for the upper limits. J Hepatol. 2017;68:798–813. https://doi.org/10.1016/j.jhep.2017.11.008.CrossRefPubMed

61.

Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl. 2014;20(6):640–8. https://doi.org/10.1002/lt.23863.CrossRefPubMed

62.

Underwood PW, Cron DC, Terjimanian MN, Wang SC, Englesbe MJ, Waits SA. Sarcopenia and failure to rescue following liver transplantation. Clin Transpl. 2015;29(12):1076–80. https://doi.org/10.1111/ctr.12629.CrossRef

63.

Krell RW, Kaul DR, Martin AR, Englesbe MJ, Sonnenday CJ, Cai S, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl. 2013;19(12):1396–402. https://doi.org/10.1002/lt.23752.CrossRefPubMed

64.

Sinclair M, Grossmann M, Hoermann R, Angus PW, Gow PJ. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. J Hepatol. 2016;65(5):906–13. https://doi.org/10.1016/j.jhep.2016.06.007.CrossRefPubMed

Titel: Should Sarcopenia Increase Priority for Transplant or Is It a Contraindication?
verfasst von: Guido Stirnimann
Maryam Ebadi
Puneeta Tandon
Aldo J. Montano-Loza
Publikationsdatum: 01.11.2018
Verlag: Springer US
Erschienen in: Current Gastroenterology Reports / Ausgabe 11/2018
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-018-0656-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Should Sarcopenia Increase Priority for Transplant or Is It a Contraindication?

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin